FemTech — the category of technology designed specifically for women’s health and biology — has been quietly having a moment. Not a moment in the “trend piece” sense, but a structural shift in what women can actually know about their own bodies, and what they can do with that knowledge.

The global FemTech market was valued at approximately $39 billion in 2024 and is projected to reach $97 billion by 2030, according to Grand View Research — growing at over 16% annually. That’s not niche. That’s a category reshaping healthcare from the inside out.

What’s changing isn’t just the technology. It’s the premise: that women’s health deserves the same level of data-driven attention, personalization, and investment as anyone else’s. Here’s where FemTech is making the most meaningful difference right now.

Cycle Tracking Has Become Actual Science

The early days of period-tracking apps were largely about predicting dates and logging symptoms. The current generation is doing something much more sophisticated: building longitudinal health data that can surface patterns in mood, energy, sleep, skin, digestion, and productivity that women often attributed to random variation or stress.

Apps like Clue, which has published peer-reviewed research on menstrual health, and Natural Cycles, the first FDA-cleared digital contraceptive, represent a new standard: tracking that generates medically relevant data, not just calendar reminders. For women who’ve spent years feeling like their bodies are unpredictable, this kind of longitudinal pattern recognition is often genuinely revelatory.

Fertility and Hormonal Health Are Getting the Data Layer They Deserved

For decades, fertility monitoring meant temperature charts and ovulation test strips. FemTech has dramatically expanded what’s possible at home. Devices like the Tempdrop wearable track basal body temperature overnight with sensor-level accuracy. At-home hormone testing platforms like Modern Fertility — now part of Ro — let women test their AMH, FSH, and other reproductive hormones for a fraction of clinic costs.

This matters because the conversation about fertility has historically happened too late — often at the point of difficulty conceiving, rather than years earlier when more options are available. FemTech is moving that conversation upstream, giving women baseline data in their 20s and 30s to inform decisions on their own timeline.

Menopause Is Finally Getting Serious Technology Attention

Menopause has been one of the most underserved areas in women’s health — and one of the most significant gaps in FemTech until recently. That’s shifting fast. Platforms like Gennev, which connects women with menopause-specialized clinicians and offers evidence-based symptom management, and Evernow, a telehealth platform focused on personalized menopause care, are filling a gap that traditional medicine has largely ignored.

For the estimated 6,000 women who enter menopause every day in the United States, having access to specialized, science-backed care — rather than being told their symptoms are “normal” and sent home — is not a luxury. It’s a health equity issue that FemTech is starting to address at scale.

Pelvic Health Is Coming Out of the Shadows

Pelvic floor dysfunction affects an estimated 1 in 3 women at some point in their lives, according to the NIH. Yet it’s been treated as something to manage privately or endure quietly — a postpartum problem that “most women have,” rather than a health condition with effective treatments.

Devices like Elvie Trainer, a biofeedback pelvic floor trainer that connects to an app, and Perifit have made guided pelvic floor therapy accessible at home. These aren’t gimmicks — they’re devices that help women see, in real time, what’s happening with muscles they’ve been told to simply “do Kegels” for, with no feedback on whether they’re doing them correctly.

Mental Health Tech Is Addressing the Gaps Specific to Women

Women are diagnosed with depression and anxiety at higher rates than men — and experience these conditions differently, with hormonal fluctuations, life transitions, and specific stressors that generic mental health apps often don’t account for. A new generation of platforms is building for this specifically.

Maven Clinic, which focuses on women’s and family health, connects users with mental health practitioners who specialize in perinatal mental health, pregnancy loss, fertility-related anxiety, and menopause-related mood changes. Brightside offers therapy and psychiatry with a clinical approach that includes hormonal context as part of assessment.

The Investment Picture Is Changing — and Why It Matters

FemTech has historically been underfunded relative to its market size and impact. Female founders in health technology receive a disproportionately small share of venture capital, and conditions that primarily affect women have received significantly less research funding than comparable conditions in men.

That’s starting to shift. The projected 16%+ annual growth rate of the FemTech market is attracting institutional investment at a new scale — which means more products, more clinical validation, and more competitive pricing. What was a niche category is becoming infrastructure.

For women, this matters beyond the products themselves. A better-funded FemTech sector means more research into conditions that have been understudied, more clinical trials that include women as primary subjects, and more technology that treats women’s health as a core priority rather than an afterthought.

How to Actually Use FemTech Well

The risk with any health technology is using it as a substitute for clinical care rather than a complement to it. The most effective approach to FemTech is to use it to generate data that you bring into conversations with healthcare providers — not to self-diagnose or self-treat based on app outputs alone.

Track consistently enough to generate meaningful patterns (at least 2–3 menstrual cycles for cycle tracking apps to be reliable). Know what the data means — many FemTech platforms now include educational content that helps you interpret your own results in context. And advocate for yourself in clinical settings by presenting your data as part of the conversation, not waiting for a provider to ask.

The best version of FemTech isn’t technology replacing healthcare. It’s technology making you a more informed, better-prepared participant in your own healthcare — which, historically, has been a significant gap.

Disclaimer: This article is for informational purposes only and does not constitute professional medical advice. Always consult a qualified healthcare provider before making changes to your health routine or relying on health technology for medical decisions.

FAQ

Q: What is FemTech?
A: FemTech refers to technology products and services designed specifically for women’s health — including reproductive health, fertility, hormonal wellness, menopause, pelvic health, and mental health conditions that disproportionately affect women.

Q: How big is the FemTech market?
A: Grand View Research estimates the global FemTech market at approximately $39 billion in 2024, projected to reach $97 billion by 2030, growing at over 16% annually.

Q: Are FemTech devices medically validated?
A: It varies. Some products — like Natural Cycles (FDA-cleared contraceptive) and certain hormone testing platforms — are clinically validated. Others are consumer wellness products without formal clinical approval. Always check the evidence base for specific devices and consult a healthcare provider.

Q: Can FemTech replace a gynecologist or primary care physician?
A: No. FemTech is most effective as a complement to clinical care — generating data and patterns that make your healthcare conversations more informed and productive, not as a substitute for professional diagnosis and treatment.

Q: What’s the best FemTech product to start with?
A: It depends on your health priorities. For cycle tracking: Clue or Natural Cycles. For fertility insight: Modern Fertility’s at-home hormone test. For pelvic health: Elvie Trainer. For menopause care: Gennev or Evernow. Start with the area of your health that currently has the least data.